Prospective, feasibility study to evaluate the safety of the EndoArt® for treatment of 30 subjects suffering from corneal edema. Followed up for 12 months.
Title: Prospective, feasibility study to evaluate the safety of the EndoArt® for treatment of subjects suffering from corneal edema Device: EndoArt® (Artificial Endothelial Layer) Intended Use: The EndoArt® device is intended for use as an endothelial kearatoprosthesis in patients with chronic cornel edema Study Design: Prospective open-label feasibility clinical study Study Objectives: To evaluate the safety of the EndoArt® implanted in subjects suffering from corneal edema. Study Hypothesis: Treatment with the EndoArt® is safe and may result in alleviating symptoms resulting from chronic corneal edema (corneal thickness). Study population: Men and women suffering from a decrease in vision due to chronic corneal edema that meet the inclusion/exclusion criteria and provide written Informed Consent will enrolled in the study. Enrollment: A total of up to 30 subjects will be enrolled. Study Duration: Completion of active enrollment is anticipated to last approximately 18 months. The primary end point will be achieved when the final study subject has completed 6 month follow up. Subject will be followed up to 12 month. Primary Safety Endpoint: The frequency and severity of all treatment-related adverse events, during and after implantation of the EndoArt® and throughout the 6 month follow-up period. Adverse events will be assessed on a continuous basis from the procedure through the study completion at 6 months. Related adverse events include: corneal perforation, melting, uncontrolled inflammation, severe infection. Secondary Efficacy Endpoints: Corneal thickness, Subjective corneal clarity, Pain as assessed by a Visual Analogue Scale (VAS) Measurement Best Corrected Distance Visual Acuity (BCDVA) Study Treatment: Subjects will be implanted with the EndoArt®
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Enrollment
22
device is intended for use as an endothelial kearatoprosthesis
International Vision Correction Research Centre (IVCRC) Universitätsklinikum Heidelberg
Heidelberg, Germany
Barzilai MC
Ashkelon, Israel
Soroka Medical Center
Beersheba, Israel
Rambam Medical Center
Haifa, Israel
Treatment-related adverse events
frequency and severity of all treatment-related adverse events
Time frame: 6 months following EndoArt implantaion
Subjective corneal clarity
corneal clarity will be graded by the investigator. Scoring is as follow: * 0- clear * 1-iris details can be seen * 2- iris details are obscure * 3- can hardly see the pupil * 4- pupil or iris details ca not be seen
Time frame: 12 months following EndoArt implantaion
Pain as assessed by a Visual Analogue Scale (VAS)
VAS is a horizontal line, 100 mm in length, anchored by word descriptors at each end. The subject marks on the line the point that he feels represents his perception of his current state.
Time frame: 12 months following EndoArt implantaion
Measurement Best Corrected Distance Visual Acuity (BCDVA)
Visual acuity on the distance chart with best manifest correction for that distance
Time frame: 12 months following EndoArt implantaion
Corneal thickness
Corneal thickness will be measured by anterior segment Optical Coherence Tomography (OCT).
Time frame: 12 months following EndoArt implantaion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Assuta Medical Center
Tel Aviv, Israel
Tel Aviv Souraski Medical Center
Tel Aviv, Israel
AMC
Amsterdam, Netherlands
IMO - Institut de Microcirurgia Ocular
Barcelona, Spain